Abstract 359P
Background
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) have shown promising efficacy in clinical trials for resected EGFR mutant NSCLC. However, it is still unclear which type of adjuvant regimens can provide best survival benefit among multiple therapeutic strategies. Herein, we performed a network meta-analysis to comprehensively compare the efficacy and safety of adjuvant treatments for resected EGFR mutant NSCLC.
Methods
Studies comparing two or more adjuvant treatments for resected EGFR mutant NSCLC were included. Study outcomes were DFS and OS with hazard ratio and adverse events with odds ratio. The primary endpoint was DFS. Registration number: PROSPERO (CRD42020184514).
Results
10 eligible trials involved 2707 patients and 6 treatments: 3 EGFR-TKIs (osimertinib, erlotinib, gefitinib), TKI following chemotherapy (CT+TKI), chemotherapy alone and placebo. Osimertinib showed the most favorable DFS, with significant superiority versus erlotinib (HR 0.4, 95% CI 0.24-0.66), gefitinib (0.42, 0.26-0.67), chemotherapy (0.23, 0.15-0.33) and placebo (0.17, 0.12- 0.24), but with no significant improvement versus CT +TKI (0.86, 0.42-1.74). CT +TKI provided the best OS benefit across assessable treatments (versus placebo, HR, 0.6 [0.11, 3.34]). OS data form osimertinib was not yet mature. Osimertinib had the fewest toxicity, whereas CT +TKI or chemotherapy alone caused most toxic effects. In subgroup analysis, EGFR-TKIs monotherapy provided more survival improvement for patients with exon 19 deletion than with L858R mutation (HR, 0.31 [0.13, 0.75] for exon 19 deletion, and 0.48 [0.35, 0.65] for L858R mutation, respectively).
Conclusions
These results showed that adjuvant EGFR-TKIs with or without chemotherapy can improve survival outcomes compared with placebo or adjuvant chemotherapy for resected EGFR-mutated NSCLC. Osimertinib provided the most DFS benefits and safety profile among the 6 treatments. Considering both efficacy and toxic effect, osimertinib is a promising agent in adjuvant setting for EGFR-mutant NSCLC, especially for those with exon 19 deletion.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yi-Long Wu.
Funding
This project supported by the Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine (2017B0303141 20 to Y.L. WU), National Natural Science Foundation of China (81872510, 81673031 to W.Z. ZHONG).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
275P - Weekly paclitaxel, carboplatin and cetuximab (PCC) combination followed by nivolumab in platinum-sensitive recurrent and /or metastatic squamous cell carcinoma of head and neck: A double institution retrospective analysis from India
Presenter: Vivek Agarwala
Session: e-Poster Display Session
276P - Sarcopenia to predict overall survival in head and neck cancer patients receiving chemotherapy: A systematic review and meta-analysis
Presenter: Felix Kwenandar
Session: e-Poster Display Session
277P - Tegafur/uracil, platinum and cetuximab (UPEx) as first line treatment in frail patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Meng-che Hsieh
Session: e-Poster Display Session
278P - Serial assessment of parotid volume changes during radical chemoradiation of locally advanced head and neck cancer: Its implications in practice of adaptive radiotherapy
Presenter: Aathira T S
Session: e-Poster Display Session
279P - Clinico pathological characteristics and survival outcome in oral cavity cancer with masticator space involvement (T4b): A retrospective single institutional experience
Presenter: Abdulla Kunnummal Palathinkara
Session: e-Poster Display Session
280P - Safety and efficacy of concurrent chemoradiotherapy for head and neck cancers in younger versus older patients: Post hoc analysis of a randomized control trial
Presenter: Vanita Noronha
Session: e-Poster Display Session
281P - Prevalence of premalignant lesions and oral cancer among tobacco-using tea plantation workers of Nilgiri Hills, Tamilnadu, India
Presenter: Delfin Lovelina Francis
Session: e-Poster Display Session
282P - Filipino head and neck cancer patients and their quality of life
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
283P - Descriptive epidemiology of head and neck cancer in Niger: First results from the National Cancer Registry
Presenter: Salamatou Mamoudou Garba
Session: e-Poster Display Session
284P - Outcomes of metronomic adjuvant chemotherapy with tegafur-uracil in locally advanced head and neck squamous cell carcinoma
Presenter: Tsung-jang Yeh
Session: e-Poster Display Session